. PCB-77 increases mRNA abundance of CYP1A1 in adipose (A) and liver (B) of LFfed mice. Mice were administered vehicle (VEH) or PCB-77 (50 mg/kg, 2 doses in weeks 1 and 2, second 2 doses in weeks 9 and 10 for 12 week mice). (A), CYP1A1 mRNA abundance was increased in adipose at 1 and 4 weeks, but not 12 weeks after PCB-77 administration. (B), CYP1A1 mRNA abundance was increased in liver at week 2, but not week 4 after PCB-77 administration. Data are mean ± SEM from n > 3 mice/group. *, P < 0.05 compared to VEH. VEH PCB77 * Plasma IL-6 (pg/mL) Figure S7 . Body weight in LF and HF-fed mice administered vehicle (VEH) or PCB-77 (50 mg/kg, doses in weeks 1, 2, 9, and 10) during the weight gain phase of HF feeding (A), and after mice are switched to a LF diet at week 12 -16 to induce weight loss (B). Body weight was increased in HF compared to LF-fed mice beginning on week 4 (A). Data are mean ± SEM from n > 5 mice/group. 
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Weeks Body Weight (g) Figure S8 . TNF-α mRNA abundance in adipose from mice during weight gain (week 12 of HF feeding), and after mice are switched to a LF diet to induce weight loss (week 16). Data are mean ± SEM from n > 3 mice/group. *, P < 0.05 compared to week 12 within treatment group. **, P < 0.05 compared to VEH within time point.
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